Atezolizumab (anti PD-L1 therapy) and bevacizumab (anti-vascular endothelial growth factor (VEGF)) was studied in the IMBrave-150 trial and was shown to be superior to sorafenib therapy in the treatment of advanced unresectable HCC [7]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.